20,394 Shares in Alimera Sciences, Inc. (NASDAQ:ALIM) Acquired by Rhumbline Advisers

Rhumbline Advisers bought a new stake in Alimera Sciences, Inc. (NASDAQ:ALIM) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 20,394 shares of the biopharmaceutical company’s stock, valued at approximately $113,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Alimera Sciences by 61.1% in the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after acquiring an additional 396,506 shares during the last quarter. Ancora Advisors LLC acquired a new position in Alimera Sciences in the 1st quarter worth about $915,000. Deltec Asset Management LLC acquired a new position in Alimera Sciences in the 2nd quarter worth about $690,000. Bank of New York Mellon Corp bought a new stake in Alimera Sciences during the 2nd quarter worth approximately $344,000. Finally, Hillsdale Investment Management Inc. bought a new position in Alimera Sciences during the 1st quarter worth $169,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

Alimera Sciences Stock Performance

NASDAQ ALIM opened at $5.54 on Tuesday. Alimera Sciences, Inc. has a one year low of $2.61 and a one year high of $5.65. The business’s fifty day moving average is $5.55 and its 200-day moving average is $4.51. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.79 and a quick ratio of 2.62. The stock has a market capitalization of $290.24 million, a price-to-earnings ratio of -3.53 and a beta of 1.25.

Alimera Sciences (NASDAQ:ALIM) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The firm had revenue of $27.00 million during the quarter, compared to the consensus estimate of $25.76 million. Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%. Equities research analysts predict that Alimera Sciences, Inc. will post -0.13 EPS for the current year.

Wall Street Analyst Weigh In

ALIM has been the subject of a number of recent analyst reports. StockNews.com initiated coverage on shares of Alimera Sciences in a research report on Monday. They set a “hold” rating for the company. HC Wainwright cut shares of Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 price objective for the company. in a research report on Tuesday, June 25th. Maxim Group reaffirmed a “hold” rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Finally, Alliance Global Partners reiterated a “neutral” rating on shares of Alimera Sciences in a report on Tuesday, June 25th.

Alimera Sciences Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).